The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress

BACKGROUND: Ovarian function suppression (OFS) has been shown to be effective as adjuvant endocrine therapy in premenopausal women with hormone receptor-positive breast cancer. However, it is currently unclear if addition of OFS to standard tamoxifen therapy after completion of adjuvant chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyun-Ah, Ahn, Sei Hyun, Nam, Seok Jin, Park, Seho, Ro, Jungsil, Im, Seock-Ah, Jung, Yong Sik, Yoon, Jung Han, Hur, Min Hee, Choi, Yoon Ji, Lee, Soo-Jung, Jeong, Joon, Cho, Se-Heon, Kim, Sung Yong, Lee, Min Hyuk, Kim, Lee Su, Moon, Byung-In, Kim, Tae Hyun, Park, Chanheun, Kim, Sei Joong, Jung, Sung Hoo, Park, Heungkyu, Gwak, Geum Hee, Kang, Sun Hee, Kim, Jong Gin, Kim, Jeryong, Choi, Su Yun, Lim, Cheol-Wan, Kim, Doyil, Yoo, Youngbum, Song, Young-Jin, Kang, Yoon-Jung, Jung, Sang Seol, Shin, Hyuk Jai, Lee, Kwan Ju, Han, Se-Hwan, Lee, Eun Sook, Han, Wonshik, Kim, Hee-Jung, Noh, Woo Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872354/
https://www.ncbi.nlm.nih.gov/pubmed/27197523
http://dx.doi.org/10.1186/s12885-016-2354-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872354/
https://www.ncbi.nlm.nih.gov/pubmed/27197523
http://dx.doi.org/10.1186/s12885-016-2354-6

Ejemplares similares